Dr.LipidDallas said:Lp(a) and cardiovascular risk: a nuance that matters.
Can confirm. Same sequence, different timescale. I had assumed I was the exception until I read this.
Adding the clinical framing, because it changes how the question reads.
Positive "side effect" of cardiovascular risk: my blood pressure dropped so much that I'm now off metoprolol entirely! My cardiologist is thrilled.
If you're on BP meds and losing weight on a GLP-1, monitor your BP at home regularly. Hypotension symptoms (dizziness, lightheadedness when standing) mean your BP meds may need reduction. Don't wait for your next scheduled appointment — call your doctor.
CarlaRPh_TPA said:Positive "side effect" of cardiovascular risk: my blood pressure dropped so much that I'm now off metoprolol entirely!
Adding a me-too, because a thread of one person's experience is not much use. The detail I would add is minor and it is already implied above.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsCarlaRPh_TPA said:Positive "side effect" of cardiovascular risk: my blood pressure dropped so much that I'm now off metoprolol entirely!
Coming at CarlaRPh_TPA’s question from a different direction. Read four things before the headline number. The population, because trial populations are selected and supported in ways that real cohorts are not. The comparator, because "better than placebo" and "better than the current standard" are different claims and get reported identically. The primary endpoint as pre-registered, because a secondary endpoint promoted after the fact is a hypothesis rather than a finding. And the completion rate, because a large effect in the half of participants who finished is a different result from a large effect in everybody enrolled.
Happy to go further on any of that.
Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. Tagging this one for the weekly digest.